ANKMJ
Ankyra Medical Journal

Ankyra Medical Journal (AnkMJ), formerly known as the Journal of Translational and Practical Medicine, regularly publishes international quality issues in the field of Medicine in the light of current information.

eISSN: 3023-655X
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Review
Type 2 diabetes mellitus: current diagnosis and treatment
Abstract
Type 2 diabetes mellitus is a globally prevalent chronic disease caused by obesity, a sedentary lifestyle, hereditary and environmental factors, and multifactorial causes. The prevalence of diabetes has increased worldwide, and its complications cause high morbidity and mortality. With the increase in diabetes and its complications, treatment costs are also increasing. Early diagnosis of type 2 diabetes, timely initiation of treatment, and prevention of complications are crucial. Management of type 2 DM is multifaceted and includes lifestyle changes, pharmacotherapy, and close monitoring of blood glucose levels. In obese individuals, weight loss has been shown to improve glycemic control and reduce the risk of complications. Pharmacologic treatment is tailored to individual needs and may include oral antidiabetic agents, injectable drugs such as insulin, and newer classes of drugs that target specific pathways involved in glucose regulation. Glycemic control is of paramount importance to reduce the risk of microvascular and macrovascular complications associated with T2DM. In conclusion, the diagnosis and treatment of type 2 diabetes require an integrated approach focusing on lifestyle changes, regular follow-up, and personalized pharmacotherapy. Implementing early interventions and maintaining optimal glycemic control are vital to preventing complications and improving the overall condition of individuals with type 2 DM.

Keywords : Type 2 diabetes mellitus, diagnosis, treatment

Download Article


1. Türkiye Endokrinoloji ve Metabolizma Derneği, Diabetes mellitusve Komplikasyonlarının Tanı, Tedavi ve İzlem Kılavuzu. 2022.
2. Association AD. 8. Pharmacologic approaches to glycemictreatment: standards of medical care in diabetes—2018. DiabetesCare. 2018;41(1):73-85.
3. Qaseem A, Barry MJ, Humphrey LL, Forciea MA, Physicians*CGCotACo. Oral pharmacologic treatment of type 2diabetes mellitus: a clinical practice guideline update fromthe American College of Physicians. Annals Inter Med.2017;166(4):279-290.
4. Association AD. Diagnosis and classification of diabetes mellitus.Diabetes Care. 2010;33(1):62-69.
5. Nathan D, Buse J, Davidson M, et al. Management ofhyperglycaemia in type 2 diabetes mellitus: a consensus algorithmfor the initiation and adjustment of therapy: update regarding thethiazolidinediones. Diabetol. 2008;51:8-11.
6. Karahan İ, Çağar A, Güngüneş A. Tip 2 diyabet tedavisindesodyum-glukoz ko-transporter 2 inhibitörleri. Ortadoğu TıpDerg. 2018;10(3):381-385.
7. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison oflipid and glycemic effects of pioglitazone and rosiglitazone inpatients with type 2 diabetes and dyslipidemia. Diabetes Care.2005;28(7):1547-1554.
8. İ ÖÜ. Diabetes mellitus: tanı ve tiplendirme. In: Kızılgül M UB,ed. 2021:s1-10:chap Birinci Basamakta Diyabet Tanı ve Tedavisi.
9. Thipsawat S. Early detection of diabetic nephropathy in patientwith type 2 diabetes mellitus: a review of the literature. DiabetesVascular Dis Res. 2021;18(6):14791641211058856.
10. Bellary S, Kyrou I, Brown JE, Bailey CJ. Type 2 diabetes mellitusin older adults: clinical considerations and management. NatureRev Endocrinol. 2021;17(9):534-548.
11. DeFronzo RA, Ferrannini E. Insulin resistance: a multifacetedsyndrome responsible for NIDDM, obesity, hypertension,dyslipidemia, and atherosclerotic cardiovascular disease. DiabetesCare. 1991;14(3):173-194.
12. Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metforminon all-cause and cardiovascular mortality in patients withcoronary artery diseases: a systematic review and an updatedmeta-analysis. Cardiovas Diabetol. 2019;18(1):1-16.
13. Echouffo-Tcheugui JB, Perreault L, Ji L, Dagogo-Jack S.Diagnosis and management of prediabetes: a review. JAMA.2023;329(14):1206-1216.
14. Lebovitz HE. Thiazolidinediones: the forgotten diabetesmedications. Current Diabetes Rep. 2019;19:1-13.
15. Bergman M. Pathophysiology of prediabetes and treatmentimplications for the prevention of type 2 diabetes mellitus. Endoc.2013;43:504-513.
16. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renaloutcomes in type 2 diabetes and nephropathy. New England JMed. 2019;380(24):2295-2306.
17. Solis-Herrera C TC, Reasner C, DeFronzo RA, Cersosimo E.Classification of diabetes mellitus. In: Feingold KR AB, Boyce A,et al. eds, Endotext. MDText.com, Inc.
18. Wulffele eM, Kooy A, De Zeeuw D, Stehouwer C, Gansevoort R.The effect of metformin on blood pressure, plasma cholesteroland triglycerides in type 2 diabetes mellitus: a systematic review. JInter Med. 2004;256(1):1-14.
19. American Diabetes Association. 2. Classification and diagnosisof diabetes: standards of medical care in diabetes-2020. DiabetesCare. 2020;43(1):14-31.
20. Petersmann A, Müller-Wieland D, Müller UA, et al. Definition,classification and diagnosis of diabetes mellitus. Experiment ClinEndocrinol Diabetes. 2019;127(1):1-7.
21. Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinicaloutcomes and adverse events associated with glucose-loweringdrugs in patients with type 2 diabetes: a meta-analysis. JAMA.2016;316(3):313-324.
22. American Diabetes Association. Standards of medical care indiabetes 2012. Diabetes Care. 2012;35:11-63.
23. Ferguson D, Finck BN. Emerging therapeutic approaches for thetreatment of NAFLD and type 2 diabetes mellitus. Nature RevEndocrinol. 2021;17(8):484-495.
24. Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a reviewon recent drug based therapeutics. Biomed Pharmacothera.2020;131:110708.
25. Ruze R, Liu T, Zou X, et al. Obesity and type 2 diabetes mellitus:connections in epidemiology, pathogenesis, and treatments.Frontiers in Endocrinol. 2023;14:1161521.
26. DeMarsilis A, Reddy N, Boutari C, et al. Pharmacotherapyof type 2 diabetes: an update and future directions. Metabol.2022:155332.
27. Tomlinson B, Li Y-H, Chan P. Evaluating gliclazide for thetreatment of type 2 diabetes mellitus. Exp Opin Pharmacothera.2022;23(17):1869-1877.
28. Dahlén AD, Dashi G, Maslov I, et al. Trends in antidiabetic drugdiscovery: FDA approved drugs, new drugs in clinical trials andglobal sales. Frontiers Pharmacol. 2022;12:807548.
29. Foretz M, Guigas B, Viollet B. Understanding the glucoregulatorymechanisms of metformin in type 2 diabetes mellitus. Nature RevEndocrinol. 2019;15(10):569-589.
30. LaMoia TE, Shulman GI. Cellular and molecular mechanisms ofmetformin action. Endocr Rev. 2021;42(1):77-96.
31. Hostalek U, Campbell I. Metformin for diabetes prevention:update of the evidence base. Current Med Res Opinion.2021;37(10):1705-1717.
32. DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE.Pioglitazone: the forgotten, cost-effective cardioprotective drugfor type 2 diabetes. Diabetes Vascul Dis Res. 2019;16(2):133-143.
33. Dash RP, Babu RJ, Srinivas NR. Reappraisal and perspectives ofclinical drug-drug interaction potential of α-glucosidase inhibitorssuch as acarbose, voglibose and miglitol in the treatment of type 2diabetes mellitus. Xenobiotica. 2018;48(1):89-108.
34. Hossain U, Das AK, Ghosh S, Sil PC. An overview on the roleof bioactive α-glucosidase inhibitors in ameliorating diabeticcomplications. Food Chemic Toxicol. 2020;145:111738.
35. Taylor SI, Yazdi ZS, Beitelshees AL. Pharmacological treatmentof hyperglycemia in type 2 diabetes. J Clin Investiga. 2021;131(2)
36. Mende CW. Chronic kidney disease and SGLT2 inhibitors: areview of the evolving treatment landscape. Advances Therap.2022:1-17.
37. Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment oftype 2 diabetes mellitus. Nature Rev Endocrinol. 2020;16(11):642-653.
38. Maselli DB, Camilleri M. Effects of GLP-1 and its analogs ongastric physiology in diabetes mellitus and obesity. Diabetes ResClin Pract. 2021;4:171-192.
39. Drucker DJ. GLP-1 physiology informs the pharmacotherapy ofobesity. Molec Metabol. 2022;57:101351.
40. Iqbal J, Wu HX, Hu N, et al. Effect of glucagon-like peptide-1receptor agonists on body weight in adults with obesity withoutdiabetes mellitus—a systematic review and meta-analysis ofrandomized control trials. Obes Rev. 2022;23(6):e13435.
41. Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide):a new weight loss drug for chronic weight management. JInvestiga Med. 2022;70(1):5-13.
42. Sims EK, Carr AL, Oram RA, DiMeglio LA, Evans-Molina C.100 years of insulin: celebrating the past, present and future ofdiabetes therapy. Nature Med. 2021;27(7):1154-1164.
43. Rachdaoui N. Insulin: the friend and the foe in the developmentof type 2 diabetes mellitus. Internat J Molec Sci. 2020;21(5):1770.
44. Cheng R, Taleb N, Stainforth-Dubois M, Rabasa-Lhoret R. Thepromising future of insulin therapy in diabetes mellitus. Am JPhysiol-Endocrinol Metab. 2021;320(5):E886-E890.
Article available in :
Volume 2, Issue 3, 2023
Page : 118-125
https://doi.org/10.51271/JTPM-0053
Article Information
Received : 01 Dec 2023
Accepted : 29 Dec 2023
Published : 31 Dec 2023
Corresponding Author :

Züleyha Erdin: Department of Internal Medicine, Abant İzzet Baysal University Hospital, Bolu, Turkey

[email protected]
Citation : Erdin Z, Çifci A. Type 2 diabetes mellitus: current diagnosis and treatment. J Transl Pract Med. 2023;2(3):118-125.

Read: 51
Download : 1353
Cited: 1
_Footer